Sometimes. Retail NAD+ strips are labeled at 100 mg per strip, which sits at or above the active load published film reviews describe, so a 100 mg strip is a demanding formulation and lower doses or two-strip servings are often the honest answer. Before any quote, the buyer needs to confirm the ingredient's dietary-ingredient status and NDI notification position with counsel, and the claims must stay in structure/function language.
Strengths commonly seen on labels
| Strength | Where it is common | Source |
|---|---|---|
| 100 mg NAD+ per strip | 30-strip pack, single active; positioned as an oral dissolving film | source |
| 100 mg NAD+ per strip | Mint-flavored single-active strip; the 100 mg tier is the retail norm | source |
| 100 mg NAD+ per serving | 30-serving oral dissolving film, single active | source |
| 100 mg NAD+ (research-use-only label) | Some 100 mg strips are sold under a not-for-human-consumption disclaimer, a signal of how unsettled the category's labeling is | source |
What fits in a film
NAD+ is a hard fit, and buyers should hear that first. Published reviews put an orodispersible film under 200 mg total weight with the active typically at 5 to 30 percent of the dry film, and one formulation group treated about 50 mg of active per film as a practical ceiling. A 100 mg NAD+ strip therefore needs either an unusually large or thick film, a very high active fraction with little room for flavor and polymer, or two strips per serving. NAD+ is also hygroscopic and sensitive to heat and moisture, and it has a sour, slightly bitter taste, so the masking load competes with the active for the same space. The realistic paths are: a 25 to 50 mg strip with honest positioning; a two-strip 100 mg serving; or a precursor. NMN is dosed in the same range and shares the loading problem; nicotinamide riboside (NR) is a smaller molecule with a GRAS notice history and its own supplier documentation, and at modest doses it fits a film more comfortably. Expect feasibility to end with a specific dose and serving recommendation, not a yes.
NAD+ and NAD-pathway projects are custom-scoped by ingredient identity, regulatory status, stability and target dose; StripWorks does not publish a NAD+ benchmark. For NMN the supported development target is up to 150 mg per strip, subject to regulatory and supplier-document review. A preliminary feasibility and price can be quoted provisionally; before final acceptance StripWorks requires a supplier dossier supporting identity, specification, safety and lawful use, plus NDI notification, GRAS support or other documentation where applicable.
NAD+, NMN, and NR: what a brief needs to say
These three are not interchangeable in a film or on a label. NAD+ (nicotinamide adenine dinucleotide) is the molecule most retail strips name; it is large, moisture-sensitive, and typically labeled at 100 mg. NMN (nicotinamide mononucleotide) is a precursor sold at similar milligram doses, with a distinct regulatory history described below. NR (nicotinamide riboside) is a smaller precursor with GRAS notifications on file for specific suppliers' forms. The brief should state which ingredient, which supplier, which salt or form, and which documentation the supplier provides, because the answer changes the formulation, the stability plan, and the regulatory review.
Formulation and taste for NAD+ films
NAD+ and NMN taste sour and faintly bitter and are hygroscopic, which affects the film's handling as well as its flavor. Citrus and berry directions work with the acidity rather than against it; mint is used for a clinical feel. Because so much of the film is active, there is limited room for sweetener and flavor, so acceptance criteria should allow a tart finish rather than demand candy-level sweetness. Film strength and tack are watched closely, since high active fractions make films brittle or sticky. Structured review rounds record one change at a time. Sugar-free builds are normal.
Who buys NAD+ strips
Buyers are longevity and healthy-aging brands, clinics and med-spas that already offer NAD+ services and want a take-home product, biohacking and performance brands, and practitioner lines. Buyers who cannot document the ingredient's regulatory position are asked to resolve that before development starts.
Packaging and stability for NAD+ films
Moisture is the first problem: NAD+ pulls water, and a wet film degrades and sticks. Individual foil-laminate sachets with a strong moisture barrier are the default, and a desiccant-backed carton or pouch is worth evaluating. Heat exposure in shipping and retail should be part of the study. The stability plan measures NAD+ content at intervals through the labeled shelf life; brands should expect this to shape the final dose, because the amount that survives is the amount that can be declared.
Regulatory and labeling notes: NDI status and claims
This is the section counsel reads first. In the United States, a dietary ingredient not marketed before October 15, 1994 is a new dietary ingredient, and the marketer must notify FDA at least 75 days before marketing with the basis for concluding it is reasonably expected to be safe. NMN's status was contested: FDA concluded in 2022 that NMN was excluded from the dietary supplement definition under the drug-preclusion provision, then in letters dated September 29, 2025 reversed that position, finding NMN was marketed as a supplement before it was authorized for drug investigation. NMN remains a new dietary ingredient, so each marketer needs an NDI notification on file or must source from a supplier whose notification covers the material; products without one remain subject to adulteration enforcement. NAD+ itself and NR must be evaluated the same way with the specific supplier. Claims stay structure/function (supports cellular energy), carry the FDA disclaimer, and are notified within 30 days. Anti-aging, disease, and reversal language is not permitted, and research-use-only labeling does not make a consumer product compliant. StripWorks does not give regulatory advice.
Private label vs custom for NAD+
There is no shortcut private-label NAD+ strip in the way there is for B12 or melatonin. Every NAD+ project is effectively custom because the dose, the ingredient form, the supplier's documentation, and the stability outcome are specific to the brand. A practical starting point is a single-active NR or lower-dose NAD+ film at a strength stability can support, with the option to extend to a two-strip serving.
How the 500-box pilot applies
A qualified NAD+ project moves to a 500-box pilot only after the dose, ingredient documentation, and stability plan are agreed: roughly 10,000 strips in 20-count boxes or 15,000 in 30-count. The pilot tests the moisture barrier, content through early stability pulls, the carton's claim language, and market response at the strength the film can actually deliver. That is a better foundation than a large run of a product whose declared amount cannot be defended.
Common questions
A qualified 500-box pilot, about 10,000 strips in 20-count boxes or 15,000 in 30-count. Feasibility, documentation review, and stability planning come before any run.
Yes, once the ingredient documentation is in order and a dose is agreed. Development samples let you judge taste, handling, and dissolve before the pilot.
It is at or above the active load published film reviews describe, so it is a demanding build. Expect a lower dose, a two-strip serving, or a precursor to be the recommendation after feasibility.
FDA's September 2025 letters concluded NMN is not excluded from the supplement definition, but it remains a new dietary ingredient requiring an NDI notification. Your counsel and supplier must confirm coverage.
NR at modest doses fits most comfortably and has GRAS notice history for some suppliers. NAD+ and NMN at 100 mg both press against the film's load ceiling.
Yes. Space for sweetener is limited at high active loads, so the finish will be tart rather than sweet.
Structure/function language only, such as supports cellular energy, with the FDA disclaimer. No anti-aging, disease, or treatment claims, and no claims of bypassing digestion.
Yes. NMN projects are scoped to a development target of up to 150 mg per strip; NAD+ projects are custom-scoped. A provisional quote can be issued first; final acceptance requires supplier regulatory documentation and a current market review.
Primary sources
- FDA, New Dietary Ingredient (NDI) Notification Process
- Venable LLP, FDA Declares Nicotinamide Mononucleotide Is a Dietary Supplement (Sept. 29, 2025 FDA letters; NDI obligations)
- Natural Products Association, FDA Reinstates NMN as Dietary Supplement After NPA Lawsuit
- Nutritional Outlook, NMN not a dietary ingredient, says FDA (2022 drug-preclusion determination)
- FDA, GRAS Notice 635: Nicotinamide riboside chloride
- FDA, Structure/Function Claims
- FDA, Dietary Supplements (overview)
- Jacob S. et al., Orodispersible Films: Current Innovations and Emerging Trends, Pharmaceutics (2023)
- Visser J.C. et al., Orodispersible films as a personalized dosage form for nursing home residents, Int J Clin Pharm (2020)
- Neuvera NAD+ strips (100 mg label)
- Connect Wellness NAD 100 mg oral strips
- Dissolvd NAD+ strips (100 mg label)
- InStrips Recharge NAD+ strips (100 mg, research-use-only disclaimer)